Module 7 quiz Flashcards
Medications that reduce the incidence of diabetic nephropathy
Insulin + ACEI or ARBs (prevention of nephropathy and HTN)
BP goal
<140/90
Action of Insulin
Stimulates uptake of glucose, amino acids, nucleotides & K promotes synthesis of complex organic molecules
Rapid acting insulin
Lispro/Humalog
Onset: 15 mins
Duration: 3-6 hours
Admin: must give with meals
Goal: Post-prandial BG control, between meals and at night
Note: Must be used with intermediate or long acting agent in DM I
Short Acting Insulin
Regular/Humalin R
Onset: 30-60 min
Duration: 6-10 hours
Admin: Must be given immediately before or after eating or via infusion pump
Goal: Post-prandial BG control when given before meals, basal control via pump
Notes: Slower onset than rapid acting, and faster onset than longer acting. Most on pumps use rapid not regular
Intermediate insulin
NPH (Humalin N/ Novolin N)
Onset: 60-120 mins
Duration: 16-24 hours
Admin: Can NOT be given at meal times to control post prandial BG. Instead BID or TID dosing.
Goal: Control b/w meals and night
Notes: Only longer acting insulin suitable for mixing with short acting (Regular, Lispro, Aspart, Gluisine)
Mixing tips: Draw short acting first to not contaminate NPH vial (clear then cloudy)
Long duration- Glargine
Onset:70min
Duration:18-24 hours
Admin: QD or BID in some to achieve full basal coverage
Goal: Prolonged control up to 24 hours
Notes:Dosing at anytime of day, must be consistent though. achieves steady state BG control throughout day
Ultralong duration
Glargine 300
Onset: 360 min
Duration: >24 hours
Admin: only insulin analog that lasts up to 42 hours
Goal: basal glycemic control
Notes: similar to glargine 100, does not have a peak
Long duration-Detemir
Onset: 60-120min
Duration: varies
Goal: basal glycemic control
Notes: slow onset, dose dependent duration of action, low doses up to 12 hours. Higher doses up to 20-24 hours
Biguanides action and SE
Metformin
-Drug of choice for initial therapy, can be used alone or in combination
-Action: does not drive blood glucose down. Inhibits glucose production in liver, reduces absorption in the gut and sensitizes insulin receptors=increased uptake
SEs: diarrhea, nausea, lactic acidosis
Sulfonylureas
Glipizide
First oral anti-diabetic drug, can be used alone or in combo
-Action: promote insulin release by stimulation of beta cells. Only used in DM II. May also increase target cell sensitivity to Insulin.
SEs: Can cause weight gain, and dose dependent hypoglycemia (may be persistent=D5 infusion)
Notes: 1st generation=less potent, more dug-drug interactions. 2nd gen=more potent, fewer interactions, used more often
Alpha Glucosidase Inhibitors
Acarbose
Monotherapy or combination therapy
Action: Act in intestines delaying absorption of carbs=reduces rise in BG after meals
SEs: R/t bacterial fermentation of carbs: flatulence, cramps, boborygmus, diarrhea, No hypoglycemia w/ monotherapy
Notes: Can decrease iron absorption. Liver dysfunction can occur-Monitor LFTs
Androgens (produced, actions, uses, adverse effects)
Produces by testes, adrenal cortex, and ovaries
Actions: promote male secondary sex characteristics
uses: management of androgen deficiency in males
Adverse effects: virilization & hepatotoxicity
Testosterone and testosterone esters
Approved for those with documented testosterone deficiency d/t hypogonadism
Indications: delayed puberty, therapy in menopausal women, cachexia, refractory anemias, drug therapy for transgender men
Adverse effects: virilization in women, girls and boys, hepatotoxicity, negative effects on blood lipids, abuse potential, thromboembolism
5 Alpha Reductase inhibitors
Finasteride
Action: Reduced DHT in blood by 70%. Does NOT reduce testosterone=promotes regression of prostate epithelial tissue and relieves mechanical obstruction
Considerations: most effective in men w/ very enlarged prostates, decrease in ejaculate and libido in 5-10%, risk for gynocomastia
Alpha receptor blockers
Flomax
Action: Blockade of alpha 1 receptors-relaxation of bladder neck (trigone/sphincter), prostate capsule, and prostatic urethra decreasing dynamic obstruction
Considerations: Therapy must be continued life long, bloackade of alpha 1 results in systemic vasodilation and may cause hypotension, overall tolerated well, may interact w/ beta blockers